HOOKIPA signs collaboration with Roche for KRAS-mutated cancer therapy; $25M upfront, up to $930M milestones

HOOKIPA Pharma Inc.

HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.
Roche licenses HB-700, an arenaviral immunotherapy for KRAS-mutated cancers; HOOKIPA conducts research through Phase 1b.
Roche obtains an exclusive option to license a second undisclosed arenaviral immunotherapy for an additional $15 million payment.
Tiered royalties of high single-digit to mid-teens percent on worldwide net sales for both programs upon commercialization.
First oncology licensing collaboration for HOOKIPA; partnership validates its arenavirus platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.